Literature DB >> 10490914

Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes.

M Khalifa1, P Daleau, a J Turgeon.   

Abstract

Venlafaxine is a newly introduced antidepressant agent. The drug causes selective inhibition of neuronal reuptake of serotonine and norepinephrine with little effect on other neurotransmitter systems. Cases of seizures, tachycardia, and QRS prolongation have been observed following drug overdose in humans. The clinical manifestations of cardiac toxicity suggest that venlafaxine may exhibit cardiac electrophysiological effects on fast conducting cells. Consequently, studies were undertaken to characterize effects of venlafaxine on the fast inward sodium current (I(Na)) of isolated guinea pig ventricular myocytes. Currents were recorded with the whole-cell configuration of the patch-clamp technique in the presence of Ca(2+) and K(+) channel blockers. Results obtained demonstrated that venlafaxine inhibits peak I(Na) in a concentration-dependent manner with an estimated IC(50) of 8. 10(-6) M. Inhibition was exclusively of a tonic nature and rate-independent. Neither kinetics of inactivation (tau(inac)= 0.652 +/- 0.020 ms, under control conditions; tau(inac)= 0.636 +/- 0.050, in the presence of 10(-5) M venlafaxine; n = 5 cells isolated from five animals) nor kinetics of recovery from inactivation of the sodium channels (tau(re)= 58.7 +/- 1.6 ms, under control conditions; tau(re)= 54.4 +/- 1.8, in the presence of 10(-5) M venlafaxine; n = 10 cells isolated from six animals) were significantly altered by 10(-5) M venlafaxine. These observations led us to conclude that venlafaxine blocks I(Na) following its binding to the resting state of the channel. Thus, the characteristics of block of I(Na) by venlafaxine are different from those usually observed with most tricyclic antidepressants or conventional class I antiarrhythmic drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10490914

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  24 in total

1.  Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose.

Authors:  Bruno Mégarbane; Vanessa Bloch; Nicolas Deye; Frédéric J Baud
Journal:  Intensive Care Med       Date:  2006-11-11       Impact factor: 17.440

2.  The Quebec Heart Institute: 50 years of excellence in cardiology.

Authors:  Gilles R Dagenais; François Philippon; Jean-Pierre Després; Jean G Dumesnil; Paul Cartier; Peter M Bogaty; Michel Lemieux; André Moisan
Journal:  Can J Cardiol       Date:  2007-10       Impact factor: 5.223

3.  A fatal case of venlafaxine overdose.

Authors:  George M Bosse; Henry A Spiller; Aaron M Collins
Journal:  J Med Toxicol       Date:  2008-03

Review 4.  Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.

Authors:  P K Gillman
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

5.  Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reports.

Authors:  Christopher Kogut; Ericka Breden Crouse; W Victor R Vieweg; Mehrul Hasnain; Adrian Baranchuk; Geneviève C Digby; Jayanthi N Koneru; Antony Fernandez; Anand Deshmukh; Jules C Hancox; Ananda K Pandurangi
Journal:  Ther Adv Drug Saf       Date:  2013-10

6.  A comparison of venlafaxine and SSRIs in deliberate self-poisoning.

Authors:  Agnes N Chan; Naren Gunja; Christopher J Ryan
Journal:  J Med Toxicol       Date:  2010-06

7.  Venlafaxine-Induced Cytotoxicity Towards Isolated Rat Hepatocytes Involves Oxidative Stress and Mitochondrial/Lysosomal Dysfunction.

Authors:  Elham Ahmadian; Hossein Babaei; Alireza Mohajjel Nayebi; Aziz Eftekhari; Mohammad Ali Eghbal
Journal:  Adv Pharm Bull       Date:  2016-12-22

8.  An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.

Authors:  Joachim Wernicke; Alberto Lledó; Joel Raskin; Daniel K Kajdasz; Fujun Wang
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

9.  Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study.

Authors:  Carlos Martinez; Themistocles L Assimes; Daniel Mines; Sophie Dell'aniello; Samy Suissa
Journal:  BMJ       Date:  2010-02-05

Review 10.  Antidepressants for the treatment of chronic pain.

Authors:  Bénédicte Verdu; Isabelle Decosterd; Thierry Buclin; Friedrich Stiefel; Alexandre Berney
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.